Friday, March 2, 2012
Thursday, March 1, 2012
Cariprazine (RGH-188)
Cariprazine (RGH-188)
looking for NDA (approval) in 2012.
Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor Antagonist–Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile
Article from Jan 21, 2010
So it seems that Cariprazine is most like Abilify. Except with the affinity for D3 receptors. also low affinity for H1 (and 5-ht2c)than abilify.
Maybe something else that wont make us sleepy, and maybe MAYBE less weight gain, eh?
it is anticipated that the clinical effects of cariprazine caused by 5-HT2A receptor activity would be considerably less.
suggesting that cariprazine may have low propensity for causing extrapyramidal symptoms.
Positive results in phase II of bipoar mania and schizophrenia trials.
Now positive results in 2 phase III.which i think only included schizophrenia.
but is also being investigated in bipolar depression and as adjunct tx for MDD.
looking for NDA (approval) in 2012.
Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor Antagonist–Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile
Article from Jan 21, 2010
So it seems that Cariprazine is most like Abilify. Except with the affinity for D3 receptors. also low affinity for H1 (and 5-ht2c)than abilify.
Maybe something else that wont make us sleepy, and maybe MAYBE less weight gain, eh?
it is anticipated that the clinical effects of cariprazine caused by 5-HT2A receptor activity would be considerably less.
suggesting that cariprazine may have low propensity for causing extrapyramidal symptoms.
Positive results in phase II of bipoar mania and schizophrenia trials.
Now positive results in 2 phase III.which i think only included schizophrenia.
but is also being investigated in bipolar depression and as adjunct tx for MDD.
Subscribe to:
Posts (Atom)